Severe but Reversible Cholestatic Liver Injury after Pioglitazone Therapy
Authors: Amar G. Pinto
Journal: Annals of Internal Medicine (2002)

Letters19 November 2002Severe but Reversible Cholestatic Liver Injury after Pioglitazone TherapyAmar G. Pinto, MD, Oscar W. Cummings, MD, and Naga Chalasani, MDAmar G. Pinto, MDIndiana University School of Medicine; Indianapolis, IN 46202. (Pinto, Cummings, Chalasani), Oscar W. Cummings, MDIndiana University School of Medicine; Indianapolis, IN 46202. (Pinto, Cummings, Chalasani), and Naga Chalasani, MDIndiana University School of Medicine; Indianapolis, IN 46202. (Pinto, Cummings, Chalasani)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-10-200211190-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Background: Pioglitazone, a second-generation thiazolidinedione, is commonly used in the management of type 2 diabetes mellitus. Unlike troglitazone, pioglitazone is generally considered safe from a hepatic standpoint. We know of no reported cases of severe hepatotoxicity resulting from its use.Objective: To describe a patient with severe cholestatic jaundice possibly due to pioglitazone.Case Report: A 49-year-old woman with a history of type 2 diabetes mellitus and hypertension was referred to us on 1 August 2000 for evaluation of recent-onset jaundice. Her baseline medications included glipizide, verapamil, and a thiazide diuretic. She had no history of any ...References1. Maeda K. Hepatocellular injury in a patient receiving pioglitazone [Letter]. Ann Intern Med. 2001;135:306. [PMID: 11511159] LinkGoogle Scholar2. May LD, Lefkowitch JH, Kram MT, Rubin DE. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med. 2002;136:449-52. [PMID: 11900497] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Indiana University School of Medicine; Indianapolis, IN 46202. (Pinto, Cummings, Chalasani) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHepatocellular Injury in a Patient Receiving Pioglitazone Kenji Maeda Mixed Hepatocellular–Cholestatic Liver Injury after Pioglitazone Therapy Louis D. May , Jay H. Lefkowitch , Michael T. Kram , and David E. Rubin Metrics Cited ByPioglitazone-Mediated Peroxisome Proliferator-Activated Receptor γ Activation Aggravates Murine Immune-Mediated HepatitisEvaluation of Drug Biliary Excretion Using Sandwich-Cultured Human HepatocytesThiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and futureDrugs and ToxinsPrediction of drug-induced liver injury using keratinocytesEvidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in manFlagging Drugs That Inhibit the Bile Salt Export PumpThiazolidinedionesHepatic injury due to drugs, herbal compounds, chemicals and toxinsImportant Elements for the Diagnosis of Drug-Induced Liver InjuryINSULINS AND OTHER HYPOGLYCEMIC DRUGSMitochondrial dysfunction and delayed hepatotoxicity: another lesson from troglitazoneDrug-Induced CholestasisPractical guidelines for diagnosis and early management of drug-induced liver injuryUse of Insulin Sensitizers in NASHThiazolidinedionesTraitement médicamenteux du diabète de type 2recommandation de bonne pratiqueEffect of thiazolidinediones on bile acid transport in rat liverPioglitazone for type 2 diabetes mellitusThiazolidinedionesReview article: the treatment of non-alcoholic steatohepatitis with thiazolidinedionesHepatic Injury in a Patient Taking RosiglitazoneEffect of Rosiglitazone on Serum Liver Biochemistries in Diabetic Patients with Normal and Elevated Baseline Liver EnzymesSecond-Generation Thiazolidinediones and HepatotoxicityHépatite aiguë sévère à la pioglitazoneThiazolidinediones as PPAR AgonistsDrug- and chemical-induced cholestasisInsulin, glucagon, and hypoglycemic drugsHepatotoxicity of thiazolidinedionesThe "Glitazones": Rosiglitazone and PioglitazoneDrug-induced liver diseaseCholestatic syndromesPioglitazone 19 November 2002Volume 137, Issue 10Page: 857KeywordsAlanine aminotransferaseBilirubinEdemaLaboratory testsLiverLiver diseasesPhosphatasesResearch laboratoriesSerum glutamic oxaloacetic transaminaseType 2 diabetes ePublished: 19 November 2002 Issue Published: 19 November 2002 CopyrightCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...